Disease Domain | Count |
---|---|
Endocrinology and Metabolic Disease | 1 |
Top 5 Drug Type | Count |
---|---|
Hormone | 1 |
Biological products | 1 |
Target |
Mechanism ACAN modulators [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism GCGR agonists [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism CALCR agonists [+1] |
Active Org.- |
Originator Org. |
Active Indication- |
Inactive Indication |
Drug Highest PhaseDiscontinued |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date15 Jan 2024 |
Sponsor / Collaborator |
Start Date07 Feb 2022 |
Sponsor / Collaborator |
Start Date08 Oct 2020 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
SB-061 ( ACAN ) | Osteoarthritis More | Phase 2 |
OXM-001 ( GCGR x GLP-1R ) | Obesity More | Preclinical |
Calcitonin(Nordic Bioscience A/S) ( CALCR ) | Osteoarthritis More | Discontinued |
KBP-042 ( Amylin receptor x CALCR ) | Obesity More | Pending |
SAN-134 ( GLP-2R ) | Osteoporosis More | Pending |